Vaccibody (private company)

See something wrong or missing? Let us know
Offices:
Oslo
Business model:
B2B
Investors:
we tracked 3 investors
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 4 transactions

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Vaccibody AS is a privately held vaccine company based on the technology conceived at the University of Oslo and Oslo University Hospital in the laboratories of Professors Bjarne Bogen and Inger Sandlie.

Vaccibody AS has developed a unique and innovative vaccine platform with the aim to treat and prevent pre-cancerous diseases or cancer as well as infectious diseases. Through its innovative design Vaccibody’s proprietary vaccine platform generates rapid, durable and broad antibody and T cell responses leading to remarkably potent vaccines.

Vaccibody has developed compelling preclinical data and initiated the first clinical trial with VB10.16, a therapeutic vaccine against cervical precancerous lesion. Also, Vaccibody has initiated development of neoantigen-based individualized cancer vaccines and is using the Vaccibody technology to generate first-in-class therapeutics to treat cancers with a high unmet medical need.

Companies with similar profile to Vaccibody:

CompanyCriteria
Norway Avexxin
46%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • At least one vc investor: Sarsia Seed Management
Sweden Asarina Pharma
44%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Norway BerGenBio
34%
  • Similar business models: B2B
  • At least one vc investor: Sarsia Seed Management
  • Total raised in a similar range: 10M+ USD
Sweden Vironova
34%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Sweden Ilya Pharma
34%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Sweden Athera
34%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Iceland 3Z Pharmaceuticals
34%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Sweden Trialbee
34%
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
Finland TILT Biotherapeutics
33%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Sweden Airsonett
33%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Finland Blueprint Genetics
33%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Sweden BoneSupport
33%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Sweden InDex Pharmaceuticals
33%
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Norway Listen AS
33%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one other investor: Inven2
Finland BC Platforms
33%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Sweden AMRA
33%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Norway OncoImmunity
33%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one other investor: RadForsk
Denmark Acarix
33%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Norway Conceptomed
33%
  • Similar verticals: Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Sweden OxThera
33%
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD